 | | Raltegravir (Isentress) |  | | Published
November 13, 2007; Updated
October 19, 2011 | Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-07-01 | | | Selected Reference | | 10. | Grinsztejn B, Nguyen B, Katlama C, et al. 48 week efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago. Abstract H-713. | |
|
|
|
